BridgeBio Oncology Therapeutics
IPOBridgeBio Oncology Therapeutics (BBOT) | Best-in-RAS
Public · South San Francisco, United States · Founded 2024 · $200.0M raised
- Headquarters
- South San Francisco
- Employees
- 51–200
- Founded
- 2024
- Business Model
- B2B
- Website
- bbotx.com
- Total Funding
- $200.0M
- Last Round
- $200.0M Series BMay 2024
- Rounds
- 1
- Type
- Public
About
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio Pharma, BBOT completed a $200M private financing in May 2024 with leading oncology investors. The company is advancing three programs — BBO-8520, BBO-10203, and BBO-11818 — targeting KRAS and PI3Kα pathway cancers.
Summary
BridgeBio Oncology Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2024. It has raised $200.0M in total across 1 round, most recently a $200.0M Series B round in May 2024. Investors include Cormorant Asset Management, Omega Funds and Deerfield Management.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...